Bristol Myers Squibb (BMY) Stock: $64 Price Target From Morgan Stanley

By Amit Chowdhry ● Apr 11, 2022
  • The shares of Bristol-Myers Squibb Co (NYSE: BMY) have received a $64 price target from Morgan Stanley. These are the details.

The shares of Bristol-Myers Squibb Co (NYSE: BMY) have received a $64 price target from Morgan Stanley. And Morgan Stanley analyst Terence Flynn assumed the company with an “Underweight” rating.

Flynn noted that despite the generally constructive backdrop for the U.S. Pharma industry, coming patent cliffs require selectivity and he believes companies that can deliver growth in the second half of the decade are best positioned. And Flynn pointed out that Bristol must navigate generic and biosimilar competition to some of its most significant franchises between now and 2030 and is in the midst of renewing its portfolio.

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.